Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2025
Purpose: Disclosure of an investor presentation (Exhibit 99.1) regarding Q3 Earnings Supplemental Materials pursuant to Regulation FD.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves solely as a notice that supplemental financial materials are available via an attached investor presentation.
Material Changes
No material changes to financial performance or operations are detailed within the text of this Form 8-K. The filing references an attached presentation for detailed data but does not summarize specific variances versus prior periods.
Guidance, Outlook, and Risks
- Management Commentary: The Company is furnishing an investor presentation to institutional investors and analysts. The content of this presentation is incorporated by reference as Exhibit 99.1.
- Forward-Looking Statements: The filing explicitly states that the information in the investor presentation may be amended or updated at any time.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Q3 Earnings Supplemental Materials) for actual financial figures, as they are not included in the 8-K text.
- Verify the availability of the investor presentation on the Company's website at www.aquestive.com under the Events and Presentations page.
- Note that the Company reserves the right to discontinue the availability of the presentation on its website at any time.
- Confirm that the presentation is not legally "filed" for liability purposes under Section 18 of the Exchange Act.